Overview

• SANA is scheduled to enter phase 2 clinical trials later this year to evaluate its effectiveness in treating obesity
• In a phase 1 trial it was well tolerated by obese volunteers and showed early signs of weight reduction and improved blood sugar control
• Animal studies demonstrated that SANA both prevented fat accumulation under high-fat diets and reversed existing obesity and related metabolic disorders
• The drug works by activating a creatine-driven thermogenic cycle in adipocytes to generate heat independently of the UCP1 protein
• As a small salicylate derivative it could be combined with GLP-1 analog therapies to boost energy expenditure without suppressing appetite